INSM · CIK 0001104506
What Insmed Incorporated told the SEC could break it.
Insmed's revenue runs through a few hands: its three largest customers accounted for 74% of total gross product revenue in 2025 (85% in 2024), so losing or reducing business with any of them would materially hurt it. Its continued U.S. revenue also leans on regulatory outcomes — ARIKAYCE's full FDA approval depends on completing an appropriate confirmatory post-marketing study (the FDA and Japan's PMDA declined to expand the label on the ARISE study alone) — and looming drug-pricing reforms, including the IRA's Medicare Drug Price Negotiation Program and proposed MFN-based rebate rules, could cut reimbursement. On the pipeline side, its supply of treprostinil palmitil, the prodrug in its TPIP candidate, comes from a single supplier in Taiwan that holds the process and drug-product patents — a single-source dependency with added China-Taiwan geopolitical risk.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Regulatory & policy
- ARIKAYCE confirmatory post-marketing study / FDA full approvalmedium
ARIKAYCE's continued U.S. revenue depends on obtaining full FDA approval via an appropriate confirmatory post-marketing study; the FDA and Japan's PMDA confirmed they would not grant label expansion based on the ARISE study alone.
“Our ability to continue to generate revenue from ARIKAYCE will depend heavily on successfully commercializing and obtaining full regulatory approval for ARIKAYCE from the FDA by conducting an appropriate confirmatory post-marketing study.”
SEC filing →As of 2026 - IRA Medicare drug-price negotiation and MFN rebate proposalsmedium
The IRA's Medicare Drug Price Negotiation Program may affect future Medicare reimbursement for Insmed's single-source drugs, and proposed MFN-based rebate rules (GLOBE/GUARD) could require rebates on eligible products for 25% of eligible Medicare beneficiaries.
“The Inflation Reduction Act (IRA) of 2022 (P.L. 117-169) has, for the first time, allowed Medicare to negotiate the price of certain high expenditure, single source Medicare Part B or Part D drugs. The Centers for Medicare & Medicaid Services has implemented a Medicare Drug Price Negotiation Program, and this program may affect future Medicare reimbursement for our drugs.”
Customer concentration
- three largest customers = 74% of gross product revenue (unnamed distributors)high
Insmed has a limited number of significant customers — its three largest accounted for 74% of total gross product revenue in 2025 (85% in 2024) — so losing or reducing business with any of them would materially harm its financial condition.
“Our three largest customers as of December 31, 2025 accounted for 74% and 85% of our total gross product revenue for the years ended December 31, 2025 and 2024, respectively.”
SEC filing →As of 2026
Sole-source dependency
- treprostinil palmitil (TPIP prodrug) from a single supplier in Taiwanmedium
Insmed's supply of treprostinil palmitil — the prodrug in its TPIP candidate — depends on a single supplier located in Taiwan that owns the manufacturing-process and crystalline drug-product patents, creating both single-source and China-Taiwan geopolitical supply risk.
“Our supply of treprostinil palmitil, the treprostinil prodrug present in TPIP, is dependent on a single supplier located in Taiwan. The supplier owns patents on its manufacturing process and crystalline drug product, and we have filed patent applications for TPIP; however, a competitor in the PAH or PH-ILD indication may claim that we or our supplier have infringed upon or misappropriated its proprietary rights.”
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its suppliers
Patheon Inc. (Thermo Fisher Scientific)
“The agreements provide for Patheon to manufacture and supply ARIKAYCE for our anticipated long-term commercial needs. Under these agreements, we are required to deliver to Patheon the required raw materials, including active pharmaceutical ingredients, and certain fixed assets needed to manufacture ARIKAYCE.”
Cited →PPD (Thermo Fisher Scientific)
“Additionally, almost all of our clinical trial work is done by CROs, such as PPD, our CRO for the ENCORE and TPIP trials, and clinical laboratories.”
Cited →PARI Pharma GmbH
“In addition, we have a commercialization agreement with PARI, the manufacturer of our drug delivery nebulizer for ARIKAYCE, to address our commercial supply needs (the Commercialization Agreement).”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch